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Abstract
Background: EBV produces miRNAs with important functions in cancer growth, tumor invasion and host immune
surveillance. The discovery of EBV miR-BARTs is recent, and most of their functions are still unknown. Nonetheless,
some new studies underline their key roles in EBV-associated malignancies.
Main body: In EBV-associated tumors, the expression profile of miR-BARTs varies according to the cell type,
autophagic process and signals received from the tumor microenvironment. By the same way of interest is the
interaction between tumor cells and the tumor environment by the release of selected EBV miR-BARTs in addition
to the tumor proteins trough tumor exosomes.
Conclusion: In this review, we discuss new findings regarding EBV miR-BARTs in Hodgkin lymphoma and gastric
cancer. The recent discovery that miRNAs are released by exosomes, including miR-BARTs, highlights the
importance of tumor and microenvironment interplay with more specific effects on the host immune response.
Keywords: EBV, Epstein-Barr virus; miRNA, Micro RNA; BART, BamHI fragment a rightward transcript, HL, Hodgkin
lymphoma; GC, Gastric carcinoma cancer
Background
Epstein-Barr virus (EBV) is a double-stranded DNA
virus that replicates in the human oral epithelium (lytic
phase) and is transmitted by saliva. Following the pri-
mary infection, EBV persists as a latent infection in B
cells and epithelial cells. About 200,000 cancer cases per
year are attributed to EBV worldwide [1]. EBV is associ-
ated with many benign and malignant lymphoprolifera-
tive disorders of B and T lymphocytes and is particularly
frequent in lymphomas related to congenital and iatro-
genic immunodeficiencies. In addition it is sometimes
associated with carcinomas (nasopharyngeal undifferen-
tiated carcinoma, gastric carcinoma and occasionally epi-
thelial tumors of the lung, breast and salivary gland) and
sarcoma (Inflammatory EBV-positive follicular dendritic
cell sarcomas and subgroup of leiomyosarcomas in im-
munodeficient individuals, particularly HIV positive).
The virus enters cells by different routes. B cells are
infected when the EBV envelope glycoprotein gp350
binds the Complement receptor type 2 (CR2/CD21) and
the entire virus is taken up by endocytosis [2]. Epithelial
cells are infected mainly by direct fusion at the cell sur-
face where several proteins act as cofactors (e.g. ephrin
receptor A2 [3], integrins [4] and nonmuscle myosin
heavy chain IIA [5]; then the viral EBV capsid is released
into the cell. In addition, the virus can be transmitted
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from B cells to epithelial cells and vice versa through the
lytic and latent infection cycles.
The role of EBV in oncogenesis is only partially
known. Multiple factors, including the EBV genome and
environmental and host genetic factors, are necessary for
oncogenesis. Viruses contribute to the development of
human tumors by inducing cell proliferation through the
abnormal activation of oncogenes or the silencing of
tumor suppressors. In addition, EBV suppresses the host
immune system. Virus reactivation, due to a decrease in
host immune status (e.g. HIV infection, organ trans-
plant), may favor the occurrence of EBV-associated lym-
phoproliferative malignancies.
During lytic infection all viral genes are expressed,
while during latent infection a limited number of viral
genes is expressed. The viral expression profile varies ac-
cording to tumor cell type (Table 1).
In the latent form, EBV infection does not produce vi-
rions and the episome is located in the nucleus of tumor
cells [6]. The latent form is favorable for EBV persist-
ence since, by reducing viral gene expression and the ex-
pression of antigens, it helps to elude immune system.
The expression of non-coding RNAs mediates immune
escape rather than cellular transformation. Persistence of
the viral episome requires production of the EBV nu-
clear antigen 1 (EBNA1) from the origin of plasmid rep-
lication Bam H1Q promoter (Fig. 1). Lytic EBV
replication was thought to destroy latently infected cells
and thereby inhibit tumorigenesis. However, recent stud-
ies found that initiation of the lytic cycle may also sup-
port EBV-driven malignancies. Recently, a new EBV
state, intermediate between the lytic and latent forms,
has been described; in this state, the expression of some
lytic genes does not result in the production of effective
virions [7]. The intermediate state of EBV originates
from intragenic deletions that frequently occur in the
BART region or in essential lytic genes (Fig. 1). The
mechanisms underlying BART deletions are poorly
understood. One hypothesis is that certain miR-BARTs
target viral lytic proteins (e.g. BZLF1 and BRLF1) and
thereby repress reactivation from latency. Wild-type
EBV occasionally executes full lytic replication, leading
to progeny production, but such cells are destined to die
or be eliminated by the immune system. It is assumed
that the intermediate state is advantageous for the virus
to block reinfection of the same cells, although produ-
cing proteins and RNAs resulted in leaky expression of
viral lytic genes but consented cell survival.
MicroRNAs
MicroRNAs (miRNAs) are short non-coding single-
stranded RNA molecules implicated in the post- tran-
scriptional regulation of genes via either translation re-
pression or RNA degradation. EBV is the first human
virus shown to encode miRNAs. EBV produces 25
miRNA precursors, which contain 49 mature miRNAs.
EBV miRNAs are all overexpressed during latency [8].
EBV miRNAs can be transferred by secreted exosomes
from infected cells. Thus, these miRNAs are potential
factors for genome regulation of both infected and unin-
fected cells that sustain the tumor microenvironment.
miRNA precursors are clustered in two regions of the
EBV genome (Fig. 1). The BamHI fragment H rightward
open reading frame 1 (BHRF1) gene encodes three
miRNA precursors (BHRF1 to 3) that generate four ma-
ture miRNAs. The BamHI fragment A rightward tran-
script (BART) region contains 22 miRNA precursors
(BART1 to 22) that produce 44 mature miRNAs [9].
The BART region is further subdivided into subclusters
1 and 2, with the miRNAs ebv-miR-BART2-5p and ebv-
miR- BART2-3p located downstream of these two clus-
ters. Distinct EBV miRNA profiles play a crucial role in
cancer by manipulating host cells. Thus, they have been
proposed as markers of distinct EBV-associated tumor
types and of poor prognosis.
Table 1 Protein patterns distinguishing different EBV states
Cell type EBV state BZLF1 BARF-1a miR- miR- EBNA proteins LMP
BARTs BHRF1s 1 2 3A 3B 3C LP 1 2A 2B EBER
Plasma cell Lytic + + + +# – – – – – – – – – +
PEL, NPC
Memory B cell Latency 1 – – + −/+ + – – – – – – – – +
Germinal center B Latency 2 – – + −/+ + – – – – + + + + +
cell, HD, NPC, BL
Naïve B cell, LCBL Latency 3 – – + + + + + + + + + + + +
Gastric carcinoma Latency 1–2 – + + – + – – – – + – + + +
a BARF1 promoter is cell-type specific: in viral latency, BARF1 is exclusively expressed in epithelial tumors such as nasopharyngeal and gastric carcinoma but not in
lymphoma. # miR-BHRF1s are restricted to lymphoblastoid cell lines (LCL) and nasal NK/T cell lymphoma. BARF and EBER, RNA; BL Burkitt lymphoma, DLCBL
Diffuse large B-cell lymphoma; EBNA EBV nuclear antigen; HD Hodgkin disease; LMP Latent membrane proteins; NPC Nasopharyngeal carcinoma; PEL Reactivity of
peripheral blood lymphocytes
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BART miRNAs and lnc
Regulatory RNAs are distinguished, by sequence length,
into small regulatory RNAs (< 100 nucleotides) and long
noncoding (lnc) RNAs (> 200 nucleotides). Both miR-
BARTs and lnc-BARTs are expressed at high levels in
EBV+ malignancies, suggesting they have a role in tumori-
genesis [10]. miR-BARTs have been mostly studied in
nasopharyngeal cancer (NPC). In this cancer, they con-
tribute to virus latency, cell proliferation and apoptosis,
metastasis and tumor recurrence, and participate in the
regulation of tumor cell metabolism and immune evasion
[11]. Alternative splicing of BARTs results in multiple
spliced forms of Lnc-BARTs, with putative open reading
frames: BARF0, RK- BARF0, RPMS1, and A73 [12]. They
did not produce proteins and are believed to regulate cell
growth by modulating host gene expression. The mechan-
ism is not yet elucidating. However, since lnc-BARTs
localize in the nucleus, some evidence resulting from stud-
ies on BART RNAs in NPC, suggest that lnc-BARTs could
mediate epigenetic regulation of gene expression by inter-
acting with DNA methylation and the chromatin remodel-
ling machinery [13]. Lnc-BARTs was found to control
Polymerase (Pol II) at the promoter region and regulate
interferon (IFN)-beta1 and chemokine-8 (CXCL8) expres-
sion in NPC [10]. However, continued investigations are
still required to fully characterize the role of lnc-BARTs
but it strongly possible that EBV adopt a strategy to ex-
press abundant levels of lnc-BARTs to suppress most anti-
genic latency EBV proteins, thus reducing host immune
response in EBV-associated malignancies where only
EBNA1 was found expressed.
In addition to the spliced BARTs, several EBV-encoded
miR-BARTs are also encoded by the intronic regions of
the BARTs. The biogenesis of miR-BARTs has been stud-
ied by Kim and Lee [14], who identified several promoters.
The P1 promoter is the predominant start site. However,
transcripts containing upstream sequences have been
identified, suggesting that there are multiple start sites
(Fig. 1). The promoter regions are possibly regulated by
SP1, Ets transcription factor, Jun family members, IRF
(interferon regulatory factor) proteins, c-myc, and C/EBP
proteins. The transcription through exon 1 and protection
from methylation around this region suggest that this re-
gion is the active template for miRNA sequences down-
stream of exon 1. A study has suggested that miR-BARTs
are mainly transcribed by RNA polymerase II and undergo
processing to be transported from the nucleus and cut at
the state of pre-miRNAs by enzymes like RNAse III
"Drosha" and endoribonuclease Dicer, similarly as happens
for cellular miRNAs [14]. It is not yet known how BART
promoters are regulated to maintain the high level of ex-
pression of BARTs seen in NPC and cancer.
Due to this important function, BARTs were proposed
as biomarkers and targets of therapy in NPC. Here, we
summarize the roles of the most important miR-BARTs,
based on both their functions and their association with
distinct EBV-associated malignancies, in Hodgkin lymph-
oma and gastric cancer.
BART miRNAs in Hodgkin lymphoma
In Hodgkin's lymphoma, there are very few cancer cells,
and these are immersed in a microenvironment
Fig. 1 Genomic map of the EBV region containing the BAMHI-I fragment. miR-BamHI fragment H rightward open reading frame 1 (BHFR1), latent
EBV-encoded nuclear antigen 3 (EBNA3), latent EBV-encoded nuclear antigen 1 (EBNA1), miR-BamHI A rightward transcripts (BARTs) in sequence
order. Genomic deletion in the EBV B958.9 strain is shown. P1, promoter 1; P2, promoter 2; Qp, Q promoter are indicated by arrows
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particularly rich in immune cells, which constitute the
inflammatory niche necessary for the tumor growth and
survival. The prognostic significance of EBV in Hodgkin
lymphoma is controversial, however some studies indi-
cate that a poorer outcome may be related to the age of
the patients and is worse in those over 50 years. Since in
the elderly the immune response is less efficient than in
young people, this observation had reinforced the im-
portance of the host immune response in the control of
EBV+ Hodgkin lymphoma [15, 16].
Hodgkin lymphoma, like NPC and NK/T cell lymph-
oma, shows a latency II type, which is characterized by
the expression of EBNA-1, LMP-1, LMP-2A, and LMP-
2B. While the EBV latent proteins have been investi-
gated intensively in Hodgkin lymphoma, the roles of
EBV miRNAs are just starting to be explored. Data so
far indicate that EBV-associated tumors upregulate a
subset of miR-BARTs that are silenced in latently nor-
mal infected cells in vivo [17]. It is not yet known how
miR-BART expression levels are regulated. A possible
mechanism is that the stability of miRNAs depends on
the presence of their target mRNA in the cell.
Recently, lnc-BARTs expression was found to be regu-
lated by NF-κB signaling in the induction of EBV lytic
replication [18, 19]. Persistent NF-κB activation, is a
hallmark of the malignant Hodgkin and Reed-sternberg
(HRS) cells [20, 21]. The latent LMP1 gene of EBV,
expressed in Hodgkin lymphoma, mimic a constitutive
activation of the CD40 receptor and thereby actives NF-
κB rescuing germinal center B-cell with inefficient im-
munoglobulin variable (IgV) sequences from apoptosis
[22]. By the same way NF-κB activation leads to the pro-
duction and release of a large quantity of pro-
inflammatory cytokines in the tumor microenvironment
and increases the lncBARTs expression (i.e mostly
RPMS1 lnc-BART [19]) that sustain either HL growth
and EBV latency.
A study that investigated miR-BARTs in Hodgkin
lymphoma found the expression of miR-BARTs 19- 3p
and 13-3p, but the overall miR-BART expression was
low compared to other malignancies [23].
Plasma BART19-3p is the most significant miRNA
marker for NPC diagnosis [24, 25]. It is highly expressed
in tumors, with a latency III like the NK/T-cell lymph-
oma [26]. Today, the role of BART19-3p is not
understood.
Of interest, recent studies showed that tumor cells, in-
cluding EBV+ Hodgkin lymphoma cells, secrete exo-
somes [27, 28]. Exosomes from Hodgkin lymphoma are
taken up by macrophages (CD68+ cells). Tumor-
associated macrophages (TAMs) have an important role
in the progression of Hodgkin lymphoma. They are a
major immune component of the tumor microenviron-
ment and a good prognostic biomarker for disease-free
survival and overall survival. TAMs are involved in vari-
ous aspects of tumor progression including aberrant
cytokine secretion, a driver of immune checkpoint
blockade particularly important in Hodgkin lymphoma
where the PD-L1 gene is amplified in tumor cells [29].
TAMs are also important in tumor matrix remodeling,
angiogenesis, and resistance to treatment [30].
Macrophages are versatile cells capable of adapting to
the signals present in the tumor microenvironment lead-
ing to different states of activation (M1, M2 and M2-
like) with distinct sets of surface receptors and effector
molecules. M1 and M2 states depend on the main cellu-
lar sources of IFN-γ (M1, enhances microbial killing and
increases cytokine production) and IL-4 (M2, fundamen-
tal to limit tissue damage caused by inflammation).
There is an association between a high infiltration of M2
macrophages (CD163+) in Hodgkin lymphoma tissue
and worse disease outcome.
Exosomes are composed of a lipid bilayer with a diam-
eter of 50–200 nm and they transport biological mole-
cules. Only exosomes derived from EBV-positive Akata
cell line, but not those from EBV-positive B95-8 cell line
having a deletion in BART cluster 2 region (Figure 1),
caused severe lymphoproliferative diseases in a human-
ized mouse model [27]. These results emphasize the role
of BARTs in lymphomagenesis. The levels of both M1
(CD68+) and M2 (CD163+) macrophages in the spleen
of mice infected with Akata are higher than in mice
B95-8-infected. Macrophages recognize phosphatidylser-
ine, also known as the “eat-me” signal, exposed by both
apoptotic bodies of lymphoma- derived exosomes and
exosomes, and the uptake of miR- BARTs from exo-
somes causes macrophage phenotypic changes (e.g. in-
creased survival and increased production of cytokines
such as pro-inflammatory tumor necrosis factor (TNF)-α
and immunosuppressive IL-10). Thus, miR-BART regu-
lates gene expression in macrophages and directs macro-
phages towards a pro-tumor inflammatory state and a
reduced direct host-defense against EBV.
miR-BART13-3p is the most frequent miR-BART in
Hodgkin lymphoma, and it is released into the circu-
lation via exosomes [23, 31]. In NPC, EBV-miR-
BART13-3p enhanced the migration of tumor cells
and caused metastasis by driving an epithelial-
mesenchymal transition via downregulation of the
tumor suppressor AB12 [32].
miR-BART13-3p has a superior diagnostic perform-
ance than anti-EBNA1 IgA serology and EBV DNA load
for NPC compared to asymptomatic EBV-infection (i.e.
healthy donors and non-NPC tumors, EBV-associated
diseases) [31].
miR-BART2-5p, an anti-sense miRNA to EBV DNA
polymerase BALF5, was found in EBV+ Hodgkin lymph-
oma cells and in macrophages [33]. This finding suggests
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that miR-BARTs, through exosomes, have a role in
Hodgkin lymphoma. Notably, miR-BART2-5p inhibited
B-cell receptor (BCR)-mediated NF-kB activation and
was upregulated during the lytic phase [34]. As a result,
the level of BALF5 protein was reduced as well as the
amount of virus released from EBV-infected cells, sug-
gesting that it protects latent cells from EBV reactivation
[35, 36]. miR-BART2-5p is abundant in the circulation
of patients with EBV+ nasal natural killer lymphoma
and NPC, so in both these cancers it is a diagnostic and
prognostic biomarker [32, 37]. miR-BART2- 5p targets
MHC class I polypeptide-related sequence B (MICB) to
evade recognition and attack by NK cells [38]. MICA
and MICB are ligands of the NKG2D receptor, which
plays an important role in the immune response by acti-
vating NK and T cells. NKG2D was detected in about
38% of NK-cell neoplasms and cytotoxic T-lymphocyte-
derived lymphomas [39]. MIC expression is restricted to
endothelial cells, fibroblasts, epithelial cells, and tumor
cells. Since NK cells efficiently recognize and kill tumor
cells bearing NKG2D ligands, a reduction of MICB on
the tumor surface potentially inhibits the “danger sig-
nals” that alerts the innate immune system, and there-
fore reduces tumor elimination.
BART miRNAs in gastric cancer
EBV+ gastric cancer represents about 10% of all gastric
cancer cases. EBV+ gastric cancer predominates in
young men and localizes mainly in the proximal region
of the stomach [40]. It is molecularly characterized by
extreme CpG hypermethylation, frequent mutations in
PIK3CA and ARID1A, lack of TP53 mutations [41, 42],
and overexpression of IFN-□ [43] and PD-L1 [44].
Deregulation of the NF-κB signaling cascade is also view
as a pro-inflammatory-pathway that induce carcinogen-
esis, either in lymphoid cells (e.g. Hodgkin lymphoma)
and in epithelial tumors (e.g. gastric cancer) [45].
In EBV-infected GC, 99% of all virally derived polyade-
nylated transcripts are from BARTs, resulting in the pro-
duction of miR-BARTs and lnc-BARTs [46]. They were
more abundant in epithelial tumor cells than in lymph-
oid cells [47].
EBV latent form expressing EBER, EBNA1 and miR-
BARTs has been detected in EBV+ gastric cancer [47].
Latent protein LMP2A has also been detected in some
cases, while LMP1 and LMP2 are often absent in non-
invasive EBV+ gastric cancer [48, 49]. Almost all EBV+
gastric cancers express high levels of nearly all miR-
BARTs, while NPC and GC did not express miR-BHRF1
[50]. EBV miR-BARTs have been reported to regulate
the expression of viral genes BZLF1 and BRLF1, to re-
duce both the lytic replication of the virus [51] and the
oncogenic latent protein LMP1 [52].
Therefore, they regulate the viral cycle and the onco-
genic transformation of gastric cells. Of note, miR-BARTs
are highly expressed (>10% of the total pool of miRNAs)
in EBV+ gastric tumor cells [53]. However, it is important
to pay attention to the effects of the tumor milieu, which
produces potent inflammatory mediators such as IFN-γ
that upregulate the transcription of mRNA targets, leading
to differences in expression of mRNAs between gastric
cancer cell lines and tissue samples [54]. EBV-positive gas-
tric cancer tissue samples had intact MHC-I antigen pres-
entation, including EBV antigen presentation, and
increased T-cell infiltration than EBV-negative gastric
cancer tumor samples [54]. These findings may explain
the better outcome of patients with EBV+ gastric cancer
than with other types of this tumor [55].
The miR-BART expression profiles of clinical samples
of EBV+ gastric cancer have been reported [56]. In that
study, miR-BART7-3p had the highest expression level,
followed by miR-BART9-3p, miR-BART1-3p, miR-
BART5-5p, miR-BART14-3p, miR-BART10-3p, miR-
BART4-5p, miR-BART1-5p, miR-BART2-5p, and miR-
BART15. Low expression was reported for miR-BART2-
3p, miR-BART7-5p, miR-BART9-5p, miR-BART10-5p,
miR-BART14-5p, miR-BART18-3p, miR-BART20-5p,
and miR-BART20-3p. According to an in-silico analysis,
this expression profile associated with oncogenesis, cell
adhesion, signal transduction, and apoptosis, all of which
are essential for the development and progression of gas-
tric cancer. However, since the discovery of miR-BARTs
is relatively recent, the functions of most miR-BARTs in
gastric cancer pathogenesis are only beginning to
emerge. A list of these miRNAs with their main func-
tions are reported in Table 2.
The low apoptotic status of EBV-positive gastric can-
cer tissue, compared to EBV-negative tissue, has been
associated with the effect of miR-BART4-5p on the ex-
pression of the pro-apoptotic BH3 interacting-domain
death agonist (Bid) [56]. The function of the pro-
apoptotic Bid gene is to mediate, by forming heterodi-
mers with either the agonist Bax or the antagonist Bcl-2,
the mitochondrial damage leading to apoptosis.
miR-BART7-3p has been hypothesized to play a role
in tumor growth and invasion through the suppression
of phosphatase and tensin homolog (PTEN) protein and
others against decapentaplegic homolog 7 (SMAD7) [57,
58]. PTEN is one of the main tumor suppressor genes
involved in the regulation of the cell cycle. SMAD7 is a
transforming growth factor beta (TGFβ) type 1 receptor
antagonist. The SMAD7/ TGFβ interaction blocks IL-
1R/TLR signaling, which subsequently reduces the ex-
pression of pro-inflammatory genes. SMAD7 production
is induced by TGFβ, but also by epidermal growth fac-
tor, IFN-γ and TNF-α. Therefore, SMAD7 may also pre-
vent metastasis in EBV+ gastric cancer. Moreover, by
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inducing a cancer stem cell-like alteration, SMAD7 enables
cells to better resist chemoradiotherapy. Gold nanoparticles
carrying an anti-miR-BART7- 3p antibody reduced tumor
growth in an animal model, suggesting that this miRNA
has a crucial role in epithelial cancer [67].
miR-BART17-5p is expressed in gastric cancer tissue
[59, 60] and in EBV+ gastric cancer cell lines [60]. High
miR-BART17-5p serum levels were found in NPC pa-
tients in association with progression and recurrence of
the tumor [68–70]. In NPC, LMP1 is the main target of
miR-BART17-5p [71]. However, since LMP1 expression
is abrogated in EBV-positive gastric cancer, the main ef-
fect of miR-BART17-5p occurs on the transcription fac-
tor Kruppel-like factor 2 (KLF2) [59]. KLF2 negatively
regulates energy metabolism of tumor cells and inflamma-
tion; thus, miRBART action on KLF2 positively favors gastric
cancer cell migration and anchorage-independent growth.
Additionally, several miR-BARTs from clusters I and II
were found to downregulate the expression of bcl2-
interacting mediators of cell death (BIM) [61]. A previ-
ous study reported an association between reduction of
BIM and progression of gastric cancer [72]. BIM was
found to play a key role in gastric cancer by reducing au-
tophagy, an adaptive response to apoptosis. Autophagy
is a common response to starvation, which prolongs cell
survival through the degradation and recycling of cellu-
lar macromolecules to provide energy and molecular
precursors [73]. Other miR- BARTs (mainly miR-
BART3-3p, miR-BART5-5p and miR-BART2-5p) were
encoded by EBV to support host immune escape of gas-
tric tumor cells.
In gastric cancer, miR-BART3-3p was found to inhibit
tumor infiltration by NK cells and macrophages, by al-
tering the senescence (temporary or permanent cell
cycle arrest)-associated secretory phenotype (SASP) [62].
It seems that miR-BART3-3p directly targets the tumor
suppressor gene TP53 and the TP53 target, p21, to pro-
duce this effect.
miR-BART5-5p also targets TP53, and thus promotes
cell survival [74]. Of interest, it also directly targets
PIAS3, an inhibitor of the activated pSTAT3 protein
[59]. pSTAT3 migrates to the nucleus where it induces
the transcription of several genes in gastric cancer. Since
the PD-L1 gene promoter contains sequences for
STAT3 binding, the result is of interest because gastric
cancers EBV-positive and those having a high microsat-
ellite instability are the best tumor candidate for im-
munological therapies (i.e. immune PD-1/PDL-1
checkpoint blockade) [44].
Another way to reduce immune surveillance is to re-
lease some miR-BARTs through exosomes.
Some miR-BARTs were found to be highly enriched in
exosomes of EBV+ gastric cancer cell lines [75]. It is im-
portant to note that only some miR-BARTs are released
in exosomes [76]. Several ways for miRNAs to enter ves-
icles have been hypothesized [77, 78]. Among the fre-
quent miR-BART in exosomes of gastric cancer is miR-
BART15-5p. This miR-BART regulates NLRP3 (NOD).
NLRP3 is an intracellular sensor of danger that activates
the NLRP3 inflammasome, leading to the release of pro-
inflammatory cytokines (e.g. IL-1β and IL-18) and to
gasdermin D-mediated pyroptotic cell death, which
Table 2 miR-BART targets and their functions in different cancers
miR-BART Target Function Disease Reference
miR-BART13-3p Tumor suppressor AB12 EMT HL, NPC [32]
mR-BART19-3p Unknown – HL, NPC, ENKL [23]
miR-BART2-5P MICB BALF5 Ligand for activator NKG2D NK receptor
RNA polymerase II and B-cell receptor
NFKB activation
GC, NPC HL, ENKL [34–38]




Tumor suppressor, pro- inflammatory, stem-like GC [56–58]
miR-BART4-5p BH3 interacting-domain
death agonist (Bid)
Pro-apoptotic protein GC [56]
miR-BART17-5p DNA transcription factor
Kruppel-like factor 2 (KLF2)




of cell death (Bim)
Pro-apoptotic protein Autophagy GC [61]
miR-BART3-3p TP53 tumor suppressor GC [62]
miR-BART5- 3p TP53 PIAS3 tumor suppressor inhibitor of pSTAT and pDL-1 GC [44, 63]
miR-BART15-5p NLRP3 inflammasome
BRUCE and TAX1BP1
pro-inflammatory cytokines such as
IL-1β and IL-18, gasdermin D- mediated
pyroptotic cell death apoptosis
GC [64–66]
EMT Epithelial-mesenchymal transition; ENKL Nasal NK7T-cell lymphoma; GC Gastric cancer; HL Hodgkin lymphoma; NPC Nasopharyngeal carcinoma
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actives the innate immune response [65, 66]. Therefore,
miBART15-5p limits inflammation to promote EBV in-
fection [78]. Moreover, miR-BART15-5p may also have
a role in the induction of apoptosis by targeting two in-
hibitory proteins of apoptosis, BRUCE and TAX1BP1
[64]. Therefore, it leads to death of tumor cells but also
of cells around the tumor, including immune cells,
through the release of exosomes.
Conclusions
Interactions between EBV miR-BARTs and Hodgkin
lymphoma and gastric cancer are still poorly understood.
Nonetheless, in recent years, the importance of these
molecules in cancer has been acknowledged. Of special
interest is the regulation of their expression in different
EBV-related malignancies. Some miR-BARTs are re-
leased through exosomes into the tumor microenviron-
ment. The mechanism to sustain miR-BART expression
and release in exosomes is unclear.
Hypermethylation is not involved. The best hypothesis
is that they are regulated by RNA targets in the tumor
cells. Modification of the tumor microenvironment
through miR-BARTs transported by exosomes is import-
ant mainly for the effect on the host immune response
and a better understanding of these biological mecha-
nisms may be helpful for the development of innovative
therapies. miR-BARTs are released by tumor cells into
blood in a stable form, and some of them are abundant
in EBV-associated malignancies. Some miR-BARTs have
already been found to be useful biomarkers for the diag-
nosis of the first occurrence or recurrence of a malig-
nancy. Several studies are currently investigating which
miR-BARTs are associated with specific EBV+ malignan-
cies and may have clinical utility. Altogether, this new
information is important for the development of novel
diagnostic and prognostic biomarkers and for identifying
targets for the development of more effective therapies,
including those that boost host immunity.
Abbreviations
EBV: Epstein-barr virus; miRNA: Micro RNA; BART: BamHI fragment A
rightward transcript; BHRF1: BamHI fragment H rightward open reading
frame 1; HL: Hodgkin lymphoma; GC: Gastric carcinoma cancer; HIV: Human
immunodeficiency virus; CR2/CD21: Complement receptor type 2;
EBNA1: EBV nuclear antigen 1; Lnc: Long noncoding RNAs;
NPC: Nasopharyngeal cancer; Pol: POLYMERASE; IFN: Interferon;
CXCL8: Chemokine 8; IRF: Interferon regulatory factor; NK: Natural killer cell;
LMP: Latent membrane protein; NF-κB: Nuclear factor-kB; TAMs: Tumor-
associated macrophages; PD-L: Programmed death ligand; IL: Interleukin;
IgV: Immunoglobulin variable; TNF: Tumor necrosis factor; MHC: Major
histocompatibility complex; MICB: MHC class I polypeptide-related sequence
B; PTEN: Phosphatase and tensin homolog; Bid: Pro-apoptotic BH3
interacting-domain death agonist; SMAD7: Decapentaplegic homolog 7;
TGFβ: Transforming growth factor beta; KLF2: Transcription factor Kruppel-
like factor 2; BIM: Bcl2-interacting mediators of cell death; STAT: Signal
transducer and activator of transcription; NLRP3: NOD-, LRR- and pyrin
domain-containing protein 3; EMT: Epithelial-mesenchymal transition;




All the authors declare that they have participated in writing the paper and
approved the final version.
Funding
No funding.
Availability of data and materials
“Not applicable”.





There are no conflicts of interest in connection with this paper, and the
material described is not under publication or consideration for publication
elsewhere.
Author details
1Immunopathology and Cancer Biomarkers, Department of Translational
Research, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano,
PN, Italy. 2Medical Oncology and Cancer Prevention, Department of Medical
Oncology, IRCCS, Centro di Riferimento Oncologico di Aviano (CRO), Aviano,
PN, Italy. 3Department of Medicine, University of Udine, Udine, Italy.
4Gastroenterology, Department of Medical Oncology, Centro di Riferimento
Oncologico di Aviano (CRO), IRCCS, Aviano, PN, Italy. 5Pathology, Department
of Translational Research, Centro di Riferimento Oncologico di Aviano (CRO),
Aviano, PN, Italy. 6Department of Medical, Surgical and Health Sciences,
University of Trieste Medical School, Trieste, Italy. 7Pediatric Hematology and
Oncology Unit, Oncology, Department, A.R.N.A.S. Ospedali Civico Di Cristina
e Benfratelli, Palermo, PN, Italy. 8Nuclear Medicine Department, Humanitas
Clinical and Research Hospital, Via Manzoni 56, 20089 Rozzano, MI, Italy.
9Department of Pathology, San Bortolo Hospital, Vicenza, VI, Italy. 10Pediatric
Hematology-Oncology, Azienda Ospedaliera Universitaria, Ospedale
Sant’Anna, Ferrara, FE, Italy. 11Pediatric Hemato-Oncology Clinic, Department
of Women’s and Children’s Health, University of Padua, Institute of Paediatric
Research Fondazione Città della Speranza, Padua, PD, Italy. 12Pediatric
Radiotherapy Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS,
Aviano, PN, Italy.
Received: 10 May 2020 Accepted: 11 June 2020
References
1. Khan G, Hashim MJ. Global burden of deaths from Epstein-Barr virus
attributable malignancies 1990-2010. Infect Agents Cancer. 2014;9:38.
2. Shannon-Lowe C, Adland E, Bell AI, Delecluse H-J, Rickinson AB, Rowe M.
Features distinguishing Epstein-Barr virus infections of epithelial cells and B
cells: viral genome expression, genome maintenance, and genome
amplification. J Virol. 2009;83:7749–60.
3. Chen J, Sathiyamoorthy K, Zhang X, Schaller S, Perez White BE, Jardetzky TS,
et al. Ephrin receptor A2 is a functional entry receptor for Epstein–Barr virus.
Nat Microbiol. 2018;3:172–80.
4. Xiao J, Palefsky JM, Herrera R, Berline J, Tugizov SM. The Epstein-Barr virus
BMRF-2 protein facilitates virus attachment to Oral epithelial cells. Virology.
2008;370:430–42.
5. Xiong D, Du Y, Wang H-B, Zhao B, Zhang H, Li Y, et al. Nonmuscle myosin
heavy chain IIA mediates Epstein–Barr virus infection of nasopharyngeal
epithelial cells. Proc Natl Acad Sci U S A. 2015;112:11036–41.
6. Fukayama M, Hayashi Y, Iwasaki Y, Chong J, Ooba T, Takizawa T, et al.
Epstein-Barr virus- associated gastric carcinoma and Epstein-Barr virus
infection of the stomach. Lab Investig. 1994;71:73–81.
7. Murata T, Okuno Y, Sato Y, Watanabe T, Kimura H. Oncogenesis of CAEBV
revealed: intragenic deletions in the viral genome and leaky expression of
lytic genes. Rev Med Virol. 2020;30:e2095.
Re et al. Infectious Agents and Cancer           (2020) 15:42 Page 7 of 9
8. Pfeffer S, Zavolan M, Grässer FA, Chien M, Russo JJ, Ju J, et al. Identification
of virus-encoded microRNAs. Science. 2004;304:734–6.
9. Fan C, Tang Y, Wang J, Xiong F, Guo C, Wang Y, et al. The emerging role of
Epstein-Barr virus encoded microRNAs in nasopharyngeal carcinoma. J
Cancer. 2018;9:2852–64.
10. Marquitz AR, Mathur A, Edwards RH, Raab-Traub N. Host gene expression is
regulated by two types of noncoding RNAs transcribed from the Epstein-
Barr virus BamHI a rightward transcript region. J Virol. 2015;89:11256–68.
11. Wang Y, Guo Z, Shu Y, Zhou H, Wang H, Zhang W. BART miRNAs: an
unimaginable force in the development of nasopharyngeal carcinoma. Eur J
Cancer Prev. 2017;26:144–50.
12. Smith PR, de Jesus O, Turner D, Hollyoake M, Karstegl CE, Griffin BE, et al.
Structure and coding content of CST (BART) family RNAs of Epstein-Barr
virus. J Virol. 2000;74:3082–92.
13. Verhoeven RJA, Tong S, Mok BW-Y, Liu J, He S, Zong J, et al. Epstein-barr
Virus BART long non- coding RNAs function as epigenetic modulators in
nasopharyngeal carcinoma. Front Oncol. 2019;9 [cited 2020 Apr 8]; Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817499/.
14. Kim DN, Lee SK. Biogenesis of Epstein-Barr virus microRNAs, vol. 365. New
York: Molecular and Cellular Biochemistry; 2012. p. 203–10.
15. Sato A, et al. Clinicaloutcome of Epstein-Barr virus-positive diffuselarge B-cell
lymphoma of the elderly in therituximab era. Cancer Sci. 2014;105(9):1170–
5.
16. Jarrett RF, et al. Scotland andNewcastle epidemiology of Hodgkin
DiseaseStudy group. Impact of tumor Epstein-Barr vi-rus status on
presenting features and outcomein age-defined subgroups of patients
withclassic Hodgkin lymphoma: a population-basedstudy. Blood. 2005;
106(7):2444–51.
17. Qiu J, Cosmopoulos K, Pegtel M, Hopmans E, Murray P, Middeldorp J, et al.
A novel persistence associated EBV miRNA expression profile is disrupted in
Neoplasia. Speck SH, editor. PLoS Pathog. 2011;7:e1002193.
18. Tsang CM, Lui VWY, Bruce JP, Pugh TJ, Lo KW. Translational genomics of
nasopharyngeal cancer. Semin Cancer Biol. 2020;61:84–100.
19. Verhoeven RJA, Tong S, Zhang G, Zong J, Chen Y, Jin D-Y, et al. NF-κB
signaling regulates expression of Epstein-Barr virus BART MicroRNAs and Long
noncoding RNAs in nasopharyngeal carcinoma. J Virol. 2016;90:6475–88.
20. von Hoff L, Kärgel E, Franke V, McShane E, Schulz-Beiss KW, Patone G, et al.
Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid
gene expression in Hodgkin lymphoma. Blood. 2019;133:1489–94.
21. Hinz M, Löser P, Mathas S, Krappmann D, Dörken B, Scheidereit C.
Constitutive NF-kappaB maintains high expression of a characteristic gene
network, including CD40, CD86, and a set of antiapoptotic genes in
Hodgkin/reed-Sternberg cells. Blood. 2001;97:2798–807.
22. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-
mediated B-cell proliferation is dependent upon latent membrane protein
1, which simulates an activated CD40 receptor. EMBO J. 1998;17:1700–9.
23. Sakamoto K, Sekizuka T, Uehara T, Hishima T, Mine S, Fukumoto H, et al.
Next-generation sequencing of miRNAs in clinical samples of Epstein–Barr
virus-associated B-cell lymphomas. Cancer Med. 2017;6:605–18.
24. Wu L, Wang J, Zhu D, Zhang S, Zhou X, Zhu W, et al. Circulating Epstein-
Barr virus microRNA profile reveals novel biomarker for nasopharyngeal
carcinoma diagnosis. Cancer Biomark. 2020;27:365–75.
25. Gao W, Wong T-S, Lv K-X, Zhang M-J, Tsang RK-Y, Chan JY-W. Detection of
Epstein-Barr virus (EBV)-encoded microRNAs in plasma of patients with
nasopharyngeal carcinoma. Head Neck-J Sci Spec Head Neck. 2019;41:780–92.
26. Motsch N, Alles J, Imig J, Zhu J, Barth S, Reineke T, et al. MicroRNA profiling
of Epstein-Barr virus-associated NK/T-cell lymphomas by deep sequencing.
PLoS One. 2012;7:e42193.
27. Higuchi H, Yamakawa N, Imadome K-I, Yahata T, Kotaki R, Ogata J, et al. Role
of exosomes as a proinflammatory mediator in the development of EBV-
associated lymphoma. Blood. 2018;131:2552–67.
28. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MAJ,
Hopmans ES, Lindenberg JL, et al. Functional delivery of viral miRNAs via
exosomes. Proc Natl Acad Sci U S A. 2010;107:6328–33.
29. De Re V, Caggiari L, Repetto O, Mussolin L, Mascarin M. Classical Hodgkin’s
lymphoma in the era of immune checkpoint inhibition. J Clin Med. 2019;
8(10):1596.
30. Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of
macrophage plasticity. Annu Rev Pathol. 2020;15:123–47.
31. Ramayanti O, Verkuijlen SAWM, Novianti P, Scheepbouwer C, Misovic B,
Koppers-Lalic D, et al. Vesicle-bound EBV-BART13-3p miRNA in circulation
distinguishes nasopharyngeal from other head and neck cancer and
asymptomatic EBV-infections. Int J Cancer. 2019;144:2555–66.
32. Huang J, Qin Y, Yang C, Wan C, Dai X, Sun Y, et al. Downregulation of ABI2
expression by EBV- miR-BART13-3p induces epithelial-mesenchymal
transition of nasopharyngeal carcinoma cells through upregulation of c-
JUN/SLUG signaling. Aging (Albany NY). 2020;12:340–58.
33. Chen Y, Fachko D, Ivanov NS, Skinner CM, Skalsky RL. Epstein-Barr virus
microRNAs regulate B cell receptor signal transduction and lytic
reactivation. Lin Z, editor. PLoS Pathog. 2019;15:e1007535.
34. van Eijndhoven MAJ, Zijlstra JM, Groenewegen NJ, Drees EEE, van Niele S,
Baglio SR, et al. Plasma vesicle miRNAs for therapy response monitoring in
Hodgkin lymphoma patients. JCI Insight. 2016;1(19):e89631.
35. Barth S, Pfuhl T, Mamiani A, Ehses C, Roemer K, Kremmer E, et al. Epstein-
Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA
polymerase BALF5. Nucleic Acids Res. 2008;36:666–75.
36. Jiang C, Chen J, Xie S, Zhang L, Xiang Y, Lung M, et al. Evaluation of
circulating EBV microRNA BART2-5p in facilitating early detection and
screening of nasopharyngeal carcinoma: tumor markers and signatures. Int J
Cancer. 2018;143:3209–17.
37. Komabayashi Y, Kishibe K, Nagato T, Ueda S, Takahara M, Harabuchi Y.
Circulating Epstein-Barr virus-encoded micro-RNAs as potential biomarkers
for nasal natural killer/T-cell lymphoma. Hematol Oncol. 2017;35:655–63.
38. Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. Diverseherpesvirus
microRNAs target the stress-induced immune ligand MICB to escape
recognition by natural killer cells. Cell Host Microbe. 2009;5:376–85.
39. Uemura Y, Isobe Y, Uchida A, Asano J, Nishio Y, Sakai H, et al. Expression of
activating natural killer-cell receptors is a hallmark of the innate-like T-cell
neoplasm in peripheral T-cell lymphomas. Cancer Sci. 2018;109:1254–62.
40. Alessandrini L, Manchi M, De Re V, Dolcetti R, Canzonieri V. Proposed
molecular and miRNA classification of gastric Cancer. Int J Mol Sci. 2018;19.
41. Cancer Genome Atlas Research Network. Comprehensive molecular
characterization ofgastric adenocarcinoma. Nature. 2014;513:202–9.
42. Cristescu R, Lee J, Nebozhyn M, Kim K-M, Ting JC, Wong SS, et al. Molecular
analysis ofgastric cancer identifies subtypes associated with distinct clinical
outcomes. Nat Med. 2015;21:449–56.
43. Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, Lacey MR, et al. Differences
in gastric carcinoma microenvironment stratify according to EBV infection
intensity: implications for possible immune adjuvant therapy. PLoS Pathog.
2013;9:e1003341.
44. Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J, et al. PD-L1 and gastric
cancer prognosis: a systematic review and meta-analysis. PLoS One. 2017;12:
e0182692.
45. Sokolova O, Naumann M. NF-κB signaling in Gastric cancer. Toxins (Basel).
2017;9(4):119.
46. Edwards RH, Marquitz AR, Raab-Traub N. Epstein-Barr virus BART microRNAs
are produced from a large intron prior to splicing. J Virol. 2008;82:9094–106.
47. Zhang X, Ye Y, Fu M, Zheng B, Qiu Q, Huang Z. Implication of viral
microRNAs in the genesis and diagnosis of Epstein-Barr virus-associated
tumors (review). Oncol Lett. 2019;18:3433–42.
48. Lung RW-M, Tong JH-M, Sung Y-M, Leung P-S, Ng DC-H, Chau S-L, et al.
Modulation of LMP2A expression by a newly identified Epstein-Barr virus-
encoded MicroRNA miR-BART22. Neoplasia. 2009;11:1174–U89.
49. Lo AKF, To KF, Lo KW, Lung RWM, Hui JWY, Liao G, et al. Modulation of
LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U
S A. 2007;104:16164–9.
50. Pandya D, Mariani M, He S, Andreoli M, Spennato M, Dowell-Martino C,
et al. Epstein-Barr virus MicroRNA expression increases aggressiveness of
solid malignancies. PLoS One. 2015;10:e0136058.
51. Jung Y-J, Choi H, Kim H, Lee SK. MicroRNA miR-BART20-5p stabilizes
Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1. J Virol.
2014;88:9027–37.
52. Ramakrishnan R, Donahue H, Garcia D, Tan J, Shimizu N, Rice AP, et al.
Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth
rate of nasal NK T cell lymphomas. PLoS One. 2011;6:e27271.
53. Hooykaas MJG, Kruse E, Wiertz EJHJ, Lebbink RJ. Comprehensive profiling
offunctional Epstein-Barr virus miRNA expression in human cell lines. BMC
Genomics. 2016;17:644.
54. Ghasemi F, Gameiro SF, Tessier TM, Maciver AH, Mymryk JS. High levels of
class IMajor histocompatibility complex mRNA are present in Epstein-Barr
virus-associated gastric adenocarcinomas. Cells. 2020;9(2):499.
Re et al. Infectious Agents and Cancer           (2020) 15:42 Page 8 of 9
55. Liu X, Liu J, Qiu H, Kong P, Chen S, Li W, et al. Prognostic significance of
Epstein-Barr virus infection in gastric cancer: a meta-analysis. BMC Cancer.
2015;15:782.
56. Shinozaki-Ushiku A, Kunita A, Isogai M, Hibiya T, Ushiku T, Takada K, et al.
Profiling of virus- encoded MicroRNAs in Epstein-Barr virus-associated
gastric carcinoma and their roles in gastric carcinogenesis. J Virol. 2015;89:
5581–91.
57. Cai L, Long Y, Chong T, Cai W, Tsang CM, Zhou X, et al. EBV-miR-BART7-3p
imposes Stemness in nasopharyngeal carcinoma cells by suppressing
SMAD7. Front Genet. 2019;10:939.
58. Cai L-M, Lyu X-M, Luo W-R, Cui X-F, Ye Y-F, Yuan C-C, et al. EBV-miR-
BART7-3p promotes the EMT and metastasis of nasopharyngeal
carcinoma cells by suppressing the tumor suppressor PTEN. Oncogene.
2015;34:2156–66.
59. Yoon JH, Min K, Lee SK. Epstein-Barr virus miR-BART17-5p promotes
migration and Anchorage- independent growth by targeting Kruppel-like
factor 2 in gastric Cancer. Microorganisms. 2020;8(2):258.
60. Treece AL, Duncan DL, Tang W, Elmore S, Morgan DR, Dominguez RL, et al.
Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma
reveal cancer-associated and Epstein-Barr virus-related expression patterns.
Lab Investig. 2016;96:661–71.
61. Marquitz AR, Mathur A, Nam CS, Raab-Traub N. The Epstein-Barr virus BART
microRNAs target the pro-apoptotic protein Bim. Virology. 2011;412:392–
400.
62. Wang J, Zheng X, Qin Z, Wei L, Lu Y, Peng Q, et al. Epstein-Barr virus miR-
BART3-3p promotes tumorigenesis by regulating the senescence pathway
in gastric cancer. J Biol Chem. 2019;294:4854–66.
63. Yoon CJ, Chang MS, Kim DH, Kim W, Koo BK, Yun S-C, et al. Epstein-Barr virus-
encoded miR- BART5-5p upregulates PD-L1 through PIAS3/pSTAT3
modulation, worsening clinical outcomesof PD-L1-positive gastric carcinomas.
Gastric Cancer. 2020; https://doi.org/10.1007/s10120-020-01059-3.
64. Choi H, Lee SK. TAX1BP1 downregulation by EBV-miR-BART15-3p
enhances chemosensitivity of gastric cancer cells to 5-FU. Arch Virol.
2017;162:369–77.
65. Swanson KV, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular
activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477–89.
66. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821–32.
67. Cai L, Li J, Zhang X, Lu Y, Wang J, Lyu X, et al. Gold nano-particles (AuNPs)
carrying anti-EBV- miR-BART7-3p inhibit growth of EBV-positive
nasopharyngeal carcinoma. Oncotarget. 2015;6:7838–50.
68. Hirai N, Wakisaka N, Kondo S, Aga M, Moriyama-Kita M, Ueno T, et al.
Potential interest inCirculating miR-BART17-5p as a post-treatment
biomarker for prediction of recurrence in Epstein- Barr virus-related
nasopharyngeal carcinoma. PLoS One. 2016;11:e0163609.
69. Gourzones C, Ferrand F-R, Amiel C, Vérillaud B, Barat A, Guérin M, et al.
Consistent high concentration of the viral microRNA BART17 in plasma
samples from nasopharyngeal carcinoma patients--evidence of non-
exosomal transport. Virol J. 2013;10:119.
70. Zheng X-H, Lu L-X, Cui C, Chen M-Y, Li X-Z, Jia W-H. Epstein-Barr virus mir-
bart1-5p detection via nasopharyngeal brush sampling is effective for
diagnosing nasopharyngeal carcinoma. Oncotarget. 2016;7:4972–80.
71. Riley KJ, Rabinowitz GS, Yario TA, Luna JM, Darnell RB, Steitz JA. EBV
andhuman microRNAs co- target oncogenic and apoptotic viral and human
genes during latency. EMBO J. 2012;31:2207–21.
72. Yano T, Ito K, Fukamachi H, Chi X-Z, Wee H-J, Inoue K, et al. The RUNX3
tumor suppressor upregulates Bim in gastric epithelial cells undergoing
transforming growth factor beta-induced apoptosis. Mol Cell Biol. 2006;26:
4474–88.
73. Kong P, Zhu X, Geng Q, Xia L, Sun X, Chen Y, et al. The microRNA-423-3p-
Bim Axis promotes Cancer progression and activates oncogenic autophagy
in gastric Cancer. Mol Ther. 2017;25:1027–37.
74. Zheng X, Wang J, Wei L, Peng Q, Gao Y, Fu Y, et al. Epstein-Barr virus
MicroRNA miR-BART5-3p inhibits p53 expression. J Virol. 2018;92(23):
e01022–18.
75. Fu M, Gu J, Jiang P, Qian H, Xu W, Zhang X. Exosomes in gastric cancer:
roles, mechanisms, and applications. Mol Cancer. 2019;18:41.
76. Gallo A, Vella S, Miele M, Timoneri F, Di Bella M, Bosi S, et al. Global profiling
of viral and cellular non-coding RNAs in Epstein-Barr virus-induced
lymphoblastoid cell lines and released exosome cargos. Cancer Lett. 2017;
388:334–43.
77. Choi H, Lee H, Kim SR, Gho YS, Lee SK. Epstein-Barr virus-encoded
microRNA BART15-3p promotes cell apoptosis partially by targeting BRUCE.
J Virol. 2013;87:8135–44.
78. Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey A-A, Pich D, McInnes
IB, et al. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3
inflammasome and IL-1β production. J Immunol. 2012;189:3795–9.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Re et al. Infectious Agents and Cancer           (2020) 15:42 Page 9 of 9
